2invest AG
Original-Research: SYGNIS AG (von GBC AG): BUY
Original-Research: SYGNIS AG – von GBC AG
Einstufung von GBC AG zu SYGNIS AG
Unternehmen: SYGNIS AG
ISIN: DE000A1RFM03
Anlass der Studie: Research Comment
Empfehlung: BUY
Kursziel: 4,05 EUR
Kursziel auf Sicht von: End FY 2015
Letzte Ratingänderung:
Analyst: Cosmin Filker, Felix Gode
Positive news flow about the direct marketing strategy; further
distribution agreements closed and new product launched
After the successful placement of the capital increase in December 2014
(gross proceeds of issue: EUR4.95 million), SYGNIS AG implemented a series
of measures for marketing its own product pipeline. As part of the new
business strategy, which focuses on more intensive use of marketing
potential, the company presented the first own product line in November
2014 with TruePrime(TM). The technology which the company has developed
itself and incorporated into TruePrime(TM) makes it possible to amplify the
entire genome from tiny sample quantities of up to individual cells. In
addition, TruePrime(TM) technology markedly reduces the occurrence of
artefacts in DNA copying.
The first product in this product line was launched in January 2015 with
the introduction of the TruePrime(TM) Single Cell WGA KIT. The plan is to
use various distribution channels as part of worldwide direct marketing to
intensively exploit the marketing potential.
Along with marketing via the newly introduced SYGNIS TruePrime(TM) online
shop, the company will draw on a range of specialised distributors. It
announced the signing of non-exclusive distribution agreements for this
purpose. International partnerships have already been established with the
German BioCat GmbH, the Spanish bioNova cientifica, s.l. the French OZYME
France and the Canadian D-MARK BIOSCIENCES. Furthermore, the second-largest
market for life science products is being addressed through the most recent
distribution agreement with the Japanese company FUNAKOSHI Co. Ltd. These
distribution agreements are particularly interesting because they cover all
future products in the TruePrime(TM) family and therefore offer potentially
high economies of scale. This has laid a foundation for the expected sales
success of the TruePrime(TM) Single Cell WGA KIT at an early stage. We are
anticipating further dynamic expansion of the distribution network.
In addition to this, introduction of the second product in the
TruePrime(TM) product line was announced on 23/02/2015. The new product
TruePrime(TM) WGA Kit amplifies DNA and the entire genome from various cell
types and limited sample volumes whilst maintaining a similarly high
quality. SYGNIS AG will also be using established distribution channels for
these products.
In view of recent successes in expanding the distribution network and in
product development, we think SYGNIS AG is making good progress in
operational terms. As these assumptions remain unchanged, we will maintain
our target price of EUR4.05 and reaffirm our BUY rating.
Die vollständige Analyse können Sie hier downloaden:
http://www.more-ir.de/d/12745.pdf
Kontakt für Rückfragen
Jörg Grunwald
Vorstand
GBC AG
Halderstraße 27
86150 Augsburg
0821 / 241133 0
research@gbc-ag.de
——————-übermittelt durch die EQS Group AG.——————-
Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw.
Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung
oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
Aktuelle News
Aktuelle Berichte
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden